Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2025 16:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update

BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
May 13, 2025 11:00 ET | Source: Athira Pharma, Inc.

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
July 31, 2024 08:05 ET | Source: Athira Pharma, Inc.

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

Fosgonimeton mitigated amyloid-β-induced toxicity, lowered pTau levels and reduced disruption of protein clearance mechanisms that may contribute to pTau pathology Fosgonimeton treatment,...
August 17, 2021 15:30 ET | Source: The Rosen Law Firm PA

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Athira Pharma, Inc. Investors With Losses Over $100K to Secure Counsel Before Important August 24 Deadline in Securities Class Action – ATHA

NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or...